Genfit S.A. (GNFTF)
Chart Events
Performance Outlook
| Previous Close | 5.0000 |
| Open | 5.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 5.0000 - 5.0000 |
| 52 Week Range | 3.3700 - 5.0000 |
| Volume | |
| Avg. Volume | 213 |
| Market Cap | 249.078M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | 3.85 |
| EPS (TTM) | 1.3000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.92 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GNFTF
Related Research
- GENFITENTA: Raising target price to $70.00ENANTA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $70.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat3 months agoArgus Research
- GlobeNewswire
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
Cash and cash equivalents totaled €222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of March 31, 2022 and revenues for the first three months of 2022.Cash position As of March 31, 2022, the Company’s cash and cash equivalents amounted to €222.2 million compared with €108.9 mi
- GlobeNewswire
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022
Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC), as well as the availability of preparatory document
- GlobeNewswire
GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents
Lille, France; Cambridge, MA; April 20, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 20, 2022 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 25, 2022, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, l
